Alnylam Pharmaceuticals Inc. reported a fourth-quarter net loss of $63.2 million, or $1.20 per share, compared with a loss of $14.3 million, or 33 cents, in the same period last year. For the year, the net loss was $106 million, or $2.11 per share, compared with a loss of $57.6 million, or $1.36, for the prior year. The Cambridge biotech cited a one-time charge of $65 million related to the restructuring of its licensing agreement with Tekmira Pharmaceuticals Corp. for the loss.
Alnylam cites charge for earnings loss
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week